Donald Egan

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

Gary J. Grover, Karin Mellström, Ye Liu et al. · Proceedings of the National Academy of Sciences · 2003 · 223 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3′-Triiodo-<scp>l</scp>-Thyronine

Gary J. Grover, Donald Egan, Paul G. Sleph et al. · Endocrinology · 2004 · 163 citations · Full text

Life Sciences, Endocrinology, Pharmacology +11

<i>N</i>-Aryl-oxazolidin-2-imine Muscle Selective Androgen Receptor Modulators Enhance Potency through Pharmacophore Reorientation

Alexandra A. Nirschl, Yan Zou, Stanley R. Krystek et al. · Journal of Medicinal Chemistry · 2009 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

The Dual Peroxisome Proliferator-Activated Receptor α/γ Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice

Effie Tozzo, Randolph Ponticiello, Joann Swartz et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 17 citations

Medicine, Endocrinology, Pharmacology +17